Confronto
Ipamorelin vs. Mod GRF (1-29)
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
170851-70-4
863288-34-0
Peso molecolare
711.86 g/mol
3367.9 g/mol
Emivita
2 h
0.5 h
Sequenza
Aib-His-D-2-Nal-D-Phe-Lys-NH2Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2Meccanismo d'azione
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Mod GRF (1-29)
Synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29). Four amino-acid substitutions (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) are intended to slow degradation by dipeptidyl peptidase-IV and increase enzymatic stability relative to native GHRH. Like the native hormone and sermorelin, it binds the GHRH receptor on somatotroph cells of the anterior pituitary; mechanistically this is expected to stimulate endogenous growth-hormone release. Unlike the DAC-conjugated CJC-1295 variant, it lacks albumin binding, so its duration of action remains short.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
3
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Ipamorelin and Mod GRF (1-29)?
- Ipamorelin is classified as "Crescita", while Mod GRF (1-29) is classified as "Crescita". Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). Mod GRF (1-29): Tetrasubstituted synthetic analogue of GHRH(1-29), traded on the grey market as "CJC-1295 without DAC". Closely related to sermorelin (GHRH 1-29); a short-acting growth-hormone-releasing-hormone analogue often combined with a GHRP/ghrelin mimetic. Not approved as a medicinal product. Direct human trials of this exact analogue are essentially absent; the factual basis relies on related GHRH(1-29) analogues. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Ipamorelin or Mod GRF (1-29)?
- The highest available evidence level is "RCT sull'uomo" for Ipamorelin and "Studio sull'uomo" for Mod GRF (1-29). A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Ipamorelin and Mod GRF (1-29) in Germany and the United States?
- Germania: Ipamorelin — Non approvato, Mod GRF (1-29) — Non approvato. Stati Uniti: Ipamorelin — Non approvato, Mod GRF (1-29) — Solo ricerca. These are factual summaries with source and review date on the individual pages.